Poractant Alfa

Summary

Poractant Alfa (CHEMBL1201622) is an approved unknown; indicated across 6 conditions including acute respiratory distress syndrome and newborn respiratory distress syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 6 conditions
• Clinical trials: 15

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201622
Name	Poractant Alfa
Type	Unknown
Max phase	4

Also known as: Curosurf, Poractant alfa, PORACTANT ALFA COMPONENT OF CHF-6440, PORACTANT ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acute respiratory distress syndrome	4	MONDO:0006502	EFO:1000637
newborn respiratory distress syndrome	4	MONDO:0700081	EFO:1000644
lung disorder	4	MONDO:0005275	EFO:0003818
severe acute respiratory syndrome	2	MONDO:0005091	EFO:0000694
hypoplastic left heart syndrome	1	MONDO:0004933	MONDO:0004933

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE4	6
Not specified	5
PHASE2	2
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06007547	PHASE4	RECRUITING	Prophylactic Minimally Invasive Surfactant Evaluation
NCT07350018	PHASE4	RECRUITING	Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome
NCT00767039	PHASE4	TERMINATED	Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants
NCT01039285	PHASE4	COMPLETED	Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia
NCT03521063	PHASE4	UNKNOWN	Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia.
NCT04199364	PHASE4	UNKNOWN	Medium vs Low Oxygen Threshold for the Surfactant Administration
NCT03959384	PHASE3	TERMINATED	Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age
NCT02452476	PHASE2	COMPLETED	A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)
NCT04384731	PHASE2	UNKNOWN	Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19
NCT04181255	PHASE1	TERMINATED	Cold Heart Study: A Randomized Pilot Trial of Surfactant Therapy
NCT00751959	Not specified	COMPLETED	Surfactant Application During Spontaneous Breathing With Continuous Positive Airway Pressure (CPAP) in Premature Infants < 27 Weeks
NCT01852461	Not specified	COMPLETED	Perfusion Index Variability in Respiratory Distress Syndrome
NCT01860014	Not specified	COMPLETED	Comparison of Two Different Natural Surfactants in the Treatment of Pulmonary Hemorrhage
NCT02482766	Not specified	COMPLETED	Efficacy of a New Technique -IN-REC-SUR-E- in Preterm Neonates With RDS
NCT02834624	Not specified	COMPLETED	Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).